It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries. (Status: 10/18/16) Despite best efforts to provide accurate information, errors may have crept in. Please let us
Continue reading QIDP Drug Update – Part 1: An Updated Who Is Who → Like this: Like Loading...
Posted in QIDP Antibiotics, The News |
Tagged Achaogen, Actelion, AeroVanc, Allergan, antibiotic blog, antibiotic development, Aradigm, Avycaz, Basilea, Baxdela, Bayer, Brilacidin, Cadazolid, Cardeas, Ceftazidime/avibactam, Cellceutix, Cempra, Cidara, Citius, CorMedix, Dalvance, daptomycin, Debiopharm Pharmaceuticals, delafloxacin, Destiny, Entasis, eravacycline, FDA, fosfomycin, Fusidic Acid, GSK, Harald Reinhart, iclaprim, Innocoll, Insmed, Ixodes, Matinas, Meiji Seika Pharma, Melinta, Merck, MGB Biopharma, Microbion, Morphochem, Motif Bio, Nabriva, Nemonoxacin, neutrolin, omadacycline, oritavancin, Paratek, plazomicin, Polyphor, QIDP, QIDP list of antibiotics, Raptor, RedHill Biopharma, Savara, Scynexis, Sivextro, Solithera, solithromycin, SPA, special protocol assessmentn, Summit, Surotomycin, Symbiomix, TaiGen, tedizolid, Tetraphase, The Medicines Company, Valley Fever Solutions, Viamet, Vical, Wockhardt, Zavante, Zinforo |
Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions
Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria → Like this: Like Loading...
Posted in Recent Literature, The News, The Viewpoint |
Tagged '10 x '20 initiative, ABSSSI, Allergan, antibiotic approvals, antibiotic blog, antibiotic pipeline, AstraZeneca, avibactam, Avycaz, Bayer, bedaquiline, BI/BLI combination, BLI, BMS, CABP, ceftaroline, Ceftazidime/avibactam, ceftolozane/tazobactam, cIAI, colistin, CRE, Cubicin, cUTI, dalbavancin, Dalvance, daptomycin, Dificid, Durata, EMA, ESBL, ESKAPE, expedited review, Fast Track, FDA, FDA Guidance, fidaxomicin, GSK, Harald Reinhart, IDSA, IMI, Johnson & Johnson, MDR pathogens, MDR-TB, MRSA, non-inferiority margins, novel antibiotics, Novexel, Orbactiv, oritavancin, P. aeruginosa, patient-reported outcomes, penem, Pfizer, PRO, QIDP, Roche, Sanofi, Sirturo, Sivextro, tazobactam, tedizolid, Teflaro, The Medicines Company, tuberculosis, vancomycin, Zinforo |
In the last decade (2000-2010), we saw the number of new antibiotic approvals drop successively each year; FDA changed the rules of the approval process without providing public guidance; many antibiotic companies fled the therapeutic area; investments were redirected to
Continue reading The 10 x ’20 Goal – Are We On Track? → Like this: Like Loading...
Posted in The News, The Viewpoint |
Tagged Allphase Pharma Consulting, antibiotic blog, antibiotic pipeline, AstraZeneca, Avycaz, aztreonam/avibactam, Basilea, Bayer, bedaquiline, ceftaroline, Ceftazidime/avibactam, ceftolozane/tazobactam, dalbavancin, Dalvance, defensin, delafloxacin, Dificid, eravacycline, FabI inhibitor, fidoxamicin, Harald Reinhart, MDR drugs, Merck, omadacycline, Orbactiv, oritavancin, Paratek, Pfizer, POL7080, Polyphor, Roche, Shionogi, Sirturo, Sivextro, tedizolid, televancin, Tetraphase, Vibativ, Zerbaxa, Zinforo |
Looking at the molecular structure of ceftazidime (CTAZ) and aztreonam (ATM), the differences are clear, and so are the similarities: ATM does not have the cephem ring structure of CTAZ, only the 4-member beta-lactam ring. However, the side chains are
Continue reading Aztreonam PLUS Avibactam – A New Bright Star in the Night Sky → Like this: Like Loading...
Posted in Recent Literature, The News |
Tagged Actavis, Allergan, Allphase Pharma Consulting, antibiotic blog, AstraZeneca, avibactam, Avycaz, aztreonam/avibactam, beta-lactamase inhibitor, BLI, ceftaroline, ceftaroline/avibactam, Ceftazidime/avibactam, colistin, CPE, fosfomycin, HAP, Harald Reinhart, MDR, NXL-104, tigecycline, VAP, Zinforo |